Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
Xiangnan GuanDuanchen SunEric LuJoshua A UrrutiaRobert Evan ReiterMatthew B RettigChristopher P EvansPrimo LaraMartin GleaveTomasz M BeerGeorge V ThomasJiaoti HuangRahul R AggarwalDavid A QuigleyAdam FoyeWilliam S ChenJack YoungrenAlana S WeinsteinFelix Y FengEric J SmallZheng XiaJoshi J AlumkalPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Copy number loss is common in enzalutamide-resistant tumors. Focal deletion of chromosome 17q22 defines a previously unappreciated molecular subset of enzalutamide-resistant mCRPC associated with poor clinical outcome.